MapLight Therapeutics (MPLT) Non Operating Income (2024 - 2025)
MapLight Therapeutics (MPLT) posted Non Operating Income of $3.8 million for Q4 2025, up 84.09% sequentially from $2.1 million in Q3 2025, and up 147.35% YoY from $1.5 million in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) Non Operating Income (2024 - 2025) Analysis & Trends
MapLight Therapeutics has reported Non Operating Income for 2 years, with the latest figure at $3.8 million in Q4 2025.
- Quarterly Non Operating Income rose 147.35% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.3 million (changed N/A YoY) and the FY2025 annual result came in at $7.9 million, up 47.8% from the prior year.
- Non Operating Income grew to $3.8 million in Q4 2025 per MPLT's latest filing, from $2.1 million in the prior quarter.
- Over five years, Non Operating Income peaked at $3.8 million in Q4 2025 and troughed at $1.5 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | MapLight Therapeutics | 629.68 Mn | 629.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 3.83 Mn |
| Sep 30, 2025 | 2.08 Mn |
| Dec 31, 2024 | 1.55 Mn |
| Sep 30, 2024 | 1.88 Mn |